Better overall clinical usage of second-generation inhibitors compared to first-generation inhibitors is related to their increased potency [151,152] and pan-inhibitory effect over the entire ErbB family of kinases, the overexpression of receptors such as HER2 being associated with tumor resistance in NSCLC patients treated with first-generation inhibitors [153,154]. Here, ERBB2 is linked to neoplasm.